Cite
Weinfurtner RJ, Raghunand N, Stringfield O, et al. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2021;doi: 10.1016/j.clbc.2021.06.016.
Weinfurtner, R. J., Raghunand, N., Stringfield, O., Abdalah, M., Niell, B. L., Ataya, D., Williams, A., Mooney, B., Rosa, M., Lee, M. C., Khakpour, N., Laronga, C., Czerniecki, B., Diaz, R., Ahmed, K., Washington, I., & Montejo, M. (2021). MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clinical breast cancer, . https://doi.org/10.1016/j.clbc.2021.06.016
Weinfurtner, R Jared, et al. "MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity." Clinical breast cancer vol. (2021). doi: https://doi.org/10.1016/j.clbc.2021.06.016
Weinfurtner RJ, Raghunand N, Stringfield O, Abdalah M, Niell BL, Ataya D, Williams A, Mooney B, Rosa M, Lee MC, Khakpour N, Laronga C, Czerniecki B, Diaz R, Ahmed K, Washington I, Montejo M. MRI Response to Pre-operative Stereotactic Ablative Body Radiotherapy (SABR) in Early Stage ER/PR+ HER2- Breast Cancer correlates with Surgical Pathology Tumor Bed Cellularity. Clin Breast Cancer. 2021 Jul 20; doi: 10.1016/j.clbc.2021.06.016. Epub 2021 Jul 20. PMID: 34384695.
Copy
Download .nbib